secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amphastar Pharmaceuticals, Inc. (AMPH)
CIK:        0001297184
Form:       8-K
Filed at:   2023-03-10T23:59:59+00:00
Accession:  0001297184-23-000026
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Amphastar enters $0.5M amendment with related party Hanxin for insulin R&D scale-up
--------------------------------------------------------------------------------

- Amendment to Contract Research Agreement dated July 5, 2022 with Nanjing Hanxin Pharmaceutical Technology Co., Ltd.
- Hanxin will perform scale-up manufacturing process development using Recombinant Human Insulin Research Cell Banks (RCBs).
- Total cost not to exceed approximately $0.5 million; payments in Chinese yuan adjusted for exchange rates.
- Related party transaction: CEO Jack Zhang and Chairman Mary Luo beneficially own majority of Hanxin; Audit Committee approved.
- Agreement term matches original contract, currently through July 5, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1297184/000129718423000026/0001297184-23-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1297184/000129718423000026/amph-20230308x8k.htm
  HTML page:      https://secwatch.observer/filing/0001297184-23-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer